Cargando…
A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
Cost-effectiveness analysis provides information on the potential value of new cancer treatments, which is particularly pertinent for decision makers as demand for treatment grows while healthcare budgets remain fixed. A range of decision-analytic modelling approaches can be used to estimate cost ef...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885507/ https://www.ncbi.nlm.nih.gov/pubmed/31485867 http://dx.doi.org/10.1007/s40258-019-00513-3 |
_version_ | 1783474746812268544 |
---|---|
author | Bullement, Ash Cranmer, Holly L. Shields, Gemma E. |
author_facet | Bullement, Ash Cranmer, Holly L. Shields, Gemma E. |
author_sort | Bullement, Ash |
collection | PubMed |
description | Cost-effectiveness analysis provides information on the potential value of new cancer treatments, which is particularly pertinent for decision makers as demand for treatment grows while healthcare budgets remain fixed. A range of decision-analytic modelling approaches can be used to estimate cost effectiveness. This study summarises the key modelling approaches considered in oncology, alongside their advantages and limitations. A review was conducted to identify single technology appraisals (STAs) submitted to the National Institute for Health and Care Excellence (NICE) and published papers reporting full economic evaluations of cancer treatments published within the last 5 years. The review was supplemented with the existing methods literature discussing cancer modelling. In total, 100 NICE STAs and 124 published studies were included. Partitioned-survival analysis (n = 54) and discrete-time state transition structures (n = 41) were the main structures submitted to NICE. Conversely, the published studies reported greater use of discrete-time state transition models (n = 102). Limited justification of model structure was provided by authors, despite an awareness in the existing literature that the model structure should be considered thoroughly and can greatly influence cost-effectiveness results. Justification for the choice of model structure was limited and studies would be improved with a thorough rationale for this choice. The strengths and weaknesses of each approach should be considered by future researchers. Alternative methods (such as multi-state modelling) are likely to be utilised more frequently in the future, and so justification of these more advanced methods is paramount to their acceptability to inform healthcare decision making. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40258-019-00513-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6885507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-68855072019-12-12 A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments Bullement, Ash Cranmer, Holly L. Shields, Gemma E. Appl Health Econ Health Policy Review Article Cost-effectiveness analysis provides information on the potential value of new cancer treatments, which is particularly pertinent for decision makers as demand for treatment grows while healthcare budgets remain fixed. A range of decision-analytic modelling approaches can be used to estimate cost effectiveness. This study summarises the key modelling approaches considered in oncology, alongside their advantages and limitations. A review was conducted to identify single technology appraisals (STAs) submitted to the National Institute for Health and Care Excellence (NICE) and published papers reporting full economic evaluations of cancer treatments published within the last 5 years. The review was supplemented with the existing methods literature discussing cancer modelling. In total, 100 NICE STAs and 124 published studies were included. Partitioned-survival analysis (n = 54) and discrete-time state transition structures (n = 41) were the main structures submitted to NICE. Conversely, the published studies reported greater use of discrete-time state transition models (n = 102). Limited justification of model structure was provided by authors, despite an awareness in the existing literature that the model structure should be considered thoroughly and can greatly influence cost-effectiveness results. Justification for the choice of model structure was limited and studies would be improved with a thorough rationale for this choice. The strengths and weaknesses of each approach should be considered by future researchers. Alternative methods (such as multi-state modelling) are likely to be utilised more frequently in the future, and so justification of these more advanced methods is paramount to their acceptability to inform healthcare decision making. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40258-019-00513-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2019-09-04 2019 /pmc/articles/PMC6885507/ /pubmed/31485867 http://dx.doi.org/10.1007/s40258-019-00513-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article Bullement, Ash Cranmer, Holly L. Shields, Gemma E. A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments |
title | A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments |
title_full | A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments |
title_fullStr | A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments |
title_full_unstemmed | A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments |
title_short | A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments |
title_sort | review of recent decision-analytic models used to evaluate the economic value of cancer treatments |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885507/ https://www.ncbi.nlm.nih.gov/pubmed/31485867 http://dx.doi.org/10.1007/s40258-019-00513-3 |
work_keys_str_mv | AT bullementash areviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments AT cranmerhollyl areviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments AT shieldsgemmae areviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments AT bullementash reviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments AT cranmerhollyl reviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments AT shieldsgemmae reviewofrecentdecisionanalyticmodelsusedtoevaluatetheeconomicvalueofcancertreatments |